Drugs / TEGTOCICLIB
TEGTOCICLIB
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07127770 | Aug → Oct 2025 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05431153 | Jun → Oct 2022 | — | Pfizer | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05262400 | Mar 2022 → Aug 2026 overdue | breast cancer | Pfizer | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04553133 | Sep 2020 → Dec 2026 expected | breast cancer, ovarian cancer, small cell lung carcinoma | Pfizer | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TEGTOCICLIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL5201870 ↗ |
| Known as | PF-07104091 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07127770 ↗ |
| Known as | Tagtociclib | ChEMBL registry synonym — accepted as the source's own label CHEMBL5201870 ↗ |
| Action | Inhibit | “Cyclin-dependent kinase-2 inhibitor” NCT07127770 ↗ |
| Modality | Small molecule | — CHEMBL5201870 ↗ |
| Route | Oral | “PF-07104091 will be administered orally” NCT04553133 ↗ |